HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-17 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
== Types == As the oldest vaccine, the smallpox vaccine has gone through several generations of medical technology. From 1796 to the 1880s, the vaccine was transmitted from one person to another through arm-to-arm vaccination. Smallpox vaccine was successfully maintained in cattle starting in the 1840s, and calf lymph vaccine became the leading smallpox vaccine in the 1880s. First-generation vaccines grown on the skin of live animals were widely distributed in the 1950s–1970s to eradicate smallpox. Second-generation vaccines were grown in chorioallantoic membrane or cell cultures for greater purity, and they were used in some areas during the smallpox eradication campaign. Third-generation vaccines are based on attenuated strains of vaccinia and saw limited use prior to the eradication of smallpox. All three generations of vaccine are available in stockpiles. First and second-generation vaccines contain live unattenuated vaccinia virus and can cause serious side effects in a small percentage of recipients, including death in 1–10 people per million vaccinations. Third-generation vaccines are much safer due to the milder side effects of the attenuated vaccinia strains. Second and third-generation vaccines are still being produced, with manufacturing capacity being built up in the 2000s due to fears of bioterrorism and biological warfare.
== External links == "GenAge entry for CAT (Homo sapiens)". Human Ageing Genomic Resources. Retrieved 2009-03-05. "Catalase". MadSci FAQ. madsci.org. Archived from the original on 2009-03-09. Retrieved 2009-03-05. "Catalase and oxidase test video". Regnvm Prokaryotae. Retrieved 2009-03-05. "EC 1.11.1.6 - catalase". Brenda: The Comprehensive Enzyme Information System. Retrieved 2009-03-05. "PeroxiBase - The peroxidase database". Swiss Institute of Bioinformatics. Archived from the original on 2008-10-13. Retrieved 2009-03-05. "Catalase Procedure". MicrobeID.com. Retrieved 2009-04-22. "Catalase Molecule of the Month". Protein Data Bank. Archived from the original on 2013-05-11. Retrieved 2013-01-08. Overview of all the structural information available in the PDB for UniProt: P04040 (Catalase) at the PDBe-KB.
It also absorbed the separatist Caprivi African National Union (CANU), which was formed to combat South African rule in the Caprivi Strip. Outside the Soviet bloc, Egypt continued training SWALA personnel. By 1964 others were also being sent to Ghana, Algeria, the People's Republic of China, and North Korea for military instruction. In June of that year, SWAPO confirmed that it was irrevocably committed to the course of armed revolution. The formation of the Organisation of African Unity (OAU)'s Liberation Committee further strengthened SWAPO's international standing and ushered in an era of unprecedented political decline for SWANU. The Liberation Committee had obtained approximately £20,000 in obligatory contributions from OAU member states; these funds were offered to both South West African nationalist movements. However, as SWANU was unwilling to guarantee its share of the £20,000 would be used for armed struggle, this grant was awarded to SWAPO instead. The OAU subsequently withdrew recognition from SWANU, leaving SWAPO as the sole beneficiary of pan-African legitimacy. With OAU assistance, SWAPO opened diplomatic offices in Lusaka, Cairo, and London. SWANU belatedly embarked on a ten-year programme to raise its own guerrilla army. In September 1965, the first unit of six SWALA guerrillas, identified simply as "Group 1", departed the Kongwa refugee camp to infiltrate South West Africa. Group 1 trekked first into Angola, before crossing the border into the Caprivi Strip.
=== World Health Organization === Vaccines developed for multinational distribution via the United Nations Children's Fund (UNICEF) require pre-qualification by the WHO to ensure international standards of quality, safety, immunogenicity, and efficacy for adoption by numerous countries. The process requires manufacturing consistency at WHO-contracted laboratories following Good Manufacturing Practice (GMP). When UN agencies are involved in vaccine licensure, individual nations collaborate by 1) issuing marketing authorization and a national license for the vaccine, its manufacturers, and distribution partners; and 2) conducting postmarketing surveillance, including records for adverse events after the vaccination program. The WHO works with national agencies to monitor inspections of manufacturing facilities and distributors for compliance with GMP and regulatory oversight. Some countries choose to buy vaccines licensed by reputable national organizations, such as EMA, FDA, or national agencies in other affluent countries, but such purchases typically are more expensive and may not have distribution resources suitable to local conditions in developing countries.
Sources: en.wikipedia.org
These resynthesis experiments provided strong evidence: lichens are a product of symbiosis. The dual hypothesis gained influential supporters; in 1878, Royal Society president Joseph Hooker publicly endorsed Schwendener's theory in his annual address, and by 1880 leading British and American textbooks presented lichens as dual organisms. By 1900 the consensus had shifted. Most botanists now viewed lichens as fungi partnered with algae or cyanobacteria and reclassified them accordingly. Dissent lingered. In a 1909 poll of 42 botanists, Bruce Fink found 18 calling lichens dual organisms, 14 insisting they were fungi, and the rest undecided. Yet even holdouts were beginning to adopt the dual view. The Finnish lichenologist Edvard Vainio (1890) folded lichens into a fungal scheme—labelling them fungi that happen to form symbioses—a move said to have cost him a professorship. The next puzzle was how to classify lichens now that their dual nature was clear. Taxonomists questioned whether to base classification on fungal traits, algal traits, or both. In practice, they chose the fungus. Since the fungus governs reproduction and form, its fruiting bodies and spores carried the most taxonomic weight. By the late 1800s, taxonomists grouped lichens by fungal traits—spore colour, septation, fruiting-body type—rather than thallus shape or algal partner. The shift broke with thallus-based schemes and aligned lichen study with modern fungal taxonomy.
== Summary table for classes of nuclides, stable and radioactive == Following is a summary table for the list of 986 nuclides with half-lives greater than one hour. A total of 251 nuclides have never been observed to decay, and are classically considered stable. Of these, 90 are believed to be absolutely stable except to proton decay (which has never been observed), while the rest are "observationally stable" and theoretically can undergo radioactive decay with extremely long half-lives. The remaining tabulated radionuclides have half-lives longer than 1 hour, and are well-characterized (see list of nuclides for a complete tabulation). They include 31 nuclides with measured half-lives longer than the estimated age of the universe (13.8 billion years), and another four nuclides with half-lives long enough (> 100 million years) that they are radioactive primordial nuclides, and may be detected on Earth, having survived from their presence in interstellar dust since before the formation of the Solar System, about 4.6 billion years ago. Another 60+ short-lived nuclides can be detected naturally as daughters of longer-lived nuclides or cosmic-ray products. The remaining known nuclides are known solely from artificial nuclear transmutation. Numbers may change slightly in the future as some nuclides now classified as stable are observed to be radioactive with very long half-lives. This is a summary table for the 986 nuclides with half-lives longer than one hour (including those that are stable), given in list of nuclides.
== Interaction with juvenile hormone == Juvenile hormone is synthesised in the corpora allata. In every insect tested, at least one of the three types of Allatostatin inhibits the biosynthesis of juvenile hormone. This is achieved by paracrine release of Allatostatin from neurons in the brain which terminate in the corpora allata. The signal is transduced by GPCR receptors, but the intracellular pathway is not yet known. Other amine and neuropeptide neurotransmitters may also inhibit juvenile hormone biosynthesis.
== Mechanism == PNGase F catalyzes the cleavage of an internal glycoside bond in an oligosaccharide. It cleaves all asparagine-linked complex, hybrid, or high mannose oligosaccharides unless the core GlcNAc contains an alpha 1,3- fucose. The asparagine residue, from which the glycan is removed, is deaminated to aspartic acid. PNGase F requires a minimum of two GlcNAc oligosaccharide residues attached to the asparagine in order for catalysis to occur. This enzyme utilizes a catalytic triad of cysteine-histidine-aspartate in its active site, which is a common motif for amidases. This motif contains a nucleophile, a proton donor, and a positive charge to stabilize the tetrahedral intermediate. The crystal structure of PNGase F from flavobacterium miningosepticum, with 1.8 Å resolution, was found to be folded in two domains, each with an eight-stranded antiparallel β barrel, or jelly roll, configuration. This structure is similar to lectins and glucanases, suggesting similarities with lectins and other carbohydrate-binding proteins.
== Treatment == Prednisone is usual drug for PMR, and treatment frequently lasts for more than a year. If the patient does not experience dramatic improvement after three days of 10–20 mg oral prednisone per day, the diagnosis should be reconsidered. Sometimes relief of symptoms occurs in only several hours. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen are ineffective in the initial treatment of PMR, but they may be used in conjunction with the maintenance dose of corticosteroid. Along with medical treatment, patients are encouraged to exercise and eat healthily, helping to maintain a strong immune system and build strong muscles and bones. A diet of fruits, vegetables, whole grains, and low-fat meat and dairy products, avoiding foods with high levels of refined sugars and salt is recommended. Research in the UK has also suggested that people with polymyalgia rheumatica would benefit from a falls assessment when first diagnosed, and regular treatment reviews.
Sources: en.wikipedia.org
== Principles and training methods == Strength training follows the fundamental principle that involves repeatedly exercising a muscle group. This is typically done by contracting the muscles during an exercise and then returning to the starting position. This process may be repeated for several repetitions until the muscles reach the point of failure. Strength training typically follows the principle of progressive overload, in which muscles are subjected to gradually increasing resistance over time to stimulate adaptation and growth. They respond by growing larger and stronger. People who are beginning strength training are in the process of training the neurological aspects of strength, including the ability of the brain to generate a rate of neuronal action potentials that will produce a muscular contraction that is close to the maximum of the muscle's potential.
=== Later elections === Gnassingbé was re-elected for a second term in 2010. In the April 2015 presidential election, Gnassingbé won a third term, defeating his main challenger, Jean-Pierre Fabre, by a margin of about 59% to 35%, according to official results. In the February 2020 presidential elections, Gnassingbé won his fourth presidential term in office as the president of Togo. According to the official result, he won with a margin of around 72% of the vote share. This enabled him to defeat his closest challenger, the former prime minister Agbeyome Kodjo who had 18%. The legitimacy of elections in Togo was widely disputed.
== Research == Townsend's research has combined advanced proteomics and drug metabolism with biochemistry to identify molecular targets affected by oxidative and nitrosative stress. Her lab has focused on understanding the events leading to the endoplasmic reticulum (ER) stress response, specifically examining stress-induced impacts on proteins involved in protein folding. Her publication record includes an H-index of over 50, with more than 13,000 citations.
== Obligations and enforcement == The conventions are legally binding, effectively under the Vienna Convention on the Law of Treaties (VCLT). The INCB, charged with monitoring treaty compliance, relies primarily on direct discussion with individual countries to address non-compliance issues. Formal drug treaty disagreements between countries over issues such as treaty compliance and amendment, import-export, jurisdiction, and extradition, are addressed in dispute provisions in each of the conventions that call for remedies including negotiation, mediation, arbitration, judicial proceedings, or other "peaceful means", or turning to the International Court of Justice. Periodically, the UN General Assembly holds special session meetings on drugs that provide a normative framework for the drug conventions. Falling out of compliance with the conventions, apart from denunciation by the UN and other countries, could have practical consequences, particularly for developing nations. The conventions regulate trade in legal pharmaceuticals, including the WHO list of essential drugs—leaving the system could make securing medicine more difficult. Being party to the three conventions is also a requirement for certain trade agreements, and for access to the European Union (EU). Enforcement measures rely largely on dialog and diplomacy. The INCB, in addition to discussion, can call out perceived non-compliance in its reports and in public statements – "naming and shaming" – and by alerting the CND and ECOSOC. Beyond that, it has no practical enforcement power.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the standard technique for purity and content. Mass spectrometry provides orthogonal confirmation of identity. The two are normally used together rather than in isolation.